Abstract
Bladder cancer treatment, namely systemic therapy, was dominated in the last three decades due to the absence of newer therapeutic options other than chemotherapy regimens. Chemotherapy, by itself, both in first and second-line seems to have achieved the modest plateau of its possibilities at the cost of non-negligible toxicity. Targeted therapies, which changed the therapy of many different tumors, seem rather ineffective in bladder cancer. More recently, a new generation of Immunotherapy based regimens represent the most promising avenue for the future systemic treatment of bladder cancer. Checkpoint inhibition, namely PD1/PD-L1 pathway inhibition, showed impressive results in many other tumor types and are expected to become a major player in the treatment of bladder cancer. Other immunotherapy strategies such as fusion proteins represent distant, although promising, options. A brief overview of the current status of bladder cancer immunotherapy is presented.
Keywords: Bladder cancer, clinical trials, immunotherapy, urothelial carcinoma.
Current Drug Targets
Title:Emerging Immunotargets in Bladder Cancer
Volume: 17 Issue: 7
Author(s): Francesco Massari, Chiara Ciccarese, Nuno Vau, Matteo Santoni, Rodolfo Montironi, Liang Cheng, Rita C. Marques, Marina Scarpelli, Jorge Fonseca, Marc R Matrana, Moch Holger, Stefano Cascinu, Giampaolo Tortora and Antonio Lopez-Beltran
Affiliation:
Keywords: Bladder cancer, clinical trials, immunotherapy, urothelial carcinoma.
Abstract: Bladder cancer treatment, namely systemic therapy, was dominated in the last three decades due to the absence of newer therapeutic options other than chemotherapy regimens. Chemotherapy, by itself, both in first and second-line seems to have achieved the modest plateau of its possibilities at the cost of non-negligible toxicity. Targeted therapies, which changed the therapy of many different tumors, seem rather ineffective in bladder cancer. More recently, a new generation of Immunotherapy based regimens represent the most promising avenue for the future systemic treatment of bladder cancer. Checkpoint inhibition, namely PD1/PD-L1 pathway inhibition, showed impressive results in many other tumor types and are expected to become a major player in the treatment of bladder cancer. Other immunotherapy strategies such as fusion proteins represent distant, although promising, options. A brief overview of the current status of bladder cancer immunotherapy is presented.
Export Options
About this article
Cite this article as:
Massari Francesco, Ciccarese Chiara, Vau Nuno, Santoni Matteo, Montironi Rodolfo, Cheng Liang, C. Marques Rita, Scarpelli Marina, Fonseca Jorge, R Matrana Marc, Holger Moch, Cascinu Stefano, Tortora Giampaolo and Lopez-Beltran Antonio, Emerging Immunotargets in Bladder Cancer, Current Drug Targets 2016; 17 (7) . https://dx.doi.org/10.2174/1389450117666160201105537
DOI https://dx.doi.org/10.2174/1389450117666160201105537 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Virtual Screening of Potential Anti-fatigue Mechanism of Polygonati Rhizoma Based on Network Pharmacology
Combinatorial Chemistry & High Throughput Screening Postmenopausal Hormone Therapy
Current Women`s Health Reviews Clinical Pharmacogenetics and Potential Application in Personalized Medicine
Current Drug Metabolism Hydroxysteroid Dehydrogenase (17β -HSD3, 17β-HSD5, and 3α-HSD3) Inhibitors:Extragonadal Regulation of Intracellular Sex Steroid Hormone Levels
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Quest for Surrogate Markers of Angiogenesis: A Paradigm for Translational Research in Tumor Angiogenesis and Anti- Angiogenesis Trials
Current Molecular Medicine Chalcones Incorporated Pyrazole Ring Inhibit Proliferation, Cell Cycle Progression, Angiogenesis and Induce Apoptosis of MCF7 Cell Line
Anti-Cancer Agents in Medicinal Chemistry Growth Inhibition of Human Non-Small Lung Cancer Cells H460 By Green Tea and Ginger Polyphenols
Anti-Cancer Agents in Medicinal Chemistry Will Medicinal Cannabinoids Prove to be Useful Clinically?
Current Drug Therapy Journey of 2′-deoxy-2′-fluoro-5-methyl-1-β-D-arabinofuranosyluracil (FMAU): from Antiviral Drug to PET Imaging Agent
Current Medicinal Chemistry A Review on Exploring Better Safety Prospects in Managing Cancer using Liposomal Combinations of Food Bioactive Compounds and Anticancer Drugs: Combisomes
Current Drug Delivery The Contractile Properties of Airway Smooth Muscle: How their Defects can be Linked to Asthmatic Airway Hyperresponsiveness?
Current Respiratory Medicine Reviews Pattern of Medication Use Among Older Inpatients in Seven Hospitals in Italy: Results from the Criteria to Assess Appropriate Medication Use Among Elderly Complex Patients (CRIME) Project
Current Drug Safety Bombacaceae Between the Ethnomedical Uses and Pharmacological Evidences: A Review
The Natural Products Journal Valproic Acid in the Complex Therapy of Malignant Tumors
Current Drug Targets Small Molecule Toxins Targeting Tumor Receptors
Current Pharmaceutical Design EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets Metabolic Targeting of Cancers: From Molecular Mechanisms to Therapeutic Strategies
Current Medicinal Chemistry The Antitumor Effects of Icaritin Against Breast Cancer is Related to Estrogen Receptors
Current Molecular Medicine Bladder Cancer Stem Cells
Current Stem Cell Research & Therapy An Overview on the Role of miR-451 in Lung Cancer: Diagnosis, Therapy, and Prognosis
MicroRNA